Open access · US-GOV
via ClinicalTrials.gov Clinical trial
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial
Authors not listed
Prince of Wales Hospital, Shatin, Hong Kong · 2024
Abstract
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-24 MST
Cite this
APA
Anonymous. (2024). RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial. <em>Prince of Wales Hospital, Shatin, Hong Kong</em>. https://clinicaltrials.gov/study/NCT06643780
Vancouver
Anonymous. RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial. Prince of Wales Hospital, Shatin, Hong Kong. 2024.
BibTeX
@misc{anon2024RANKli,
title = {RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: A Randomized, Double-blind, Double-dummy, Active-Controlled Trial},
author = {Anonymous},
journal = {Prince of Wales Hospital, Shatin, Hong Kong},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Regeneron Pharmaceuticals 2013
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia
Yonsei University 2024
Open access · US-GOV
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
ADC Therapeutics S.A. 2022
Open access · US-GOV
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Novartis Pharmaceuticals 2025
Open access · US-GOV
A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension
WestVac Biopharma Co., Ltd. 2021
Open access · US-GOV